MRNA Stock Plunges 18% After Leaked Melanoma Vaccine Data Misses High Hopes

Moderna (MRNA) stock fell 18% after leaked melanoma vaccine data underwhelmed investors. Analysts at TD Cowen maintained a 'Hold' rating with a $90 price target, while Wells Fargo advised buying Merck (MRK) on weakness. Retail sentiment for MRNA turned bearish, and MRK sentiment shifted to neutral. MRNA is up 600% YTD, MRK up 40%.

Original reporting
Published Oct 22, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MRNA Stock Plunges 18% After Leaked Melanoma Vaccine Data Misses High Hopes — source image
Decision brief

The 30-second read

$MRNABearishHigh
01

Why it matters

The leak led to a rapid downgrade by analysts and a shift in retail sentiment from neutral to bearish, driving the 18% price drop.

02

Market read

The event is a material, same‑day catalyst for MRNA, creating immediate trading opportunities.

03

What to watch

Potential future regulatory approvals or partnership deals could mitigate the short‑term impact.

Relevance 7/10Novelty 7/10Timing: today

Background

Moderna's melanoma vaccine data was leaked, prompting analyst commentary and retail sentiment shifts.

Company-level read

Ticker impact

$MRNABearishHigh confidence
Context

MRNA stock plunged 18% after leaked melanoma vaccine data fell short of high expectations.

Expected impact

likely continued pressure as investors reassess the vaccine's commercial potential

Evidence & confidence

The leak caused an immediate 18% drop; no mitigating news follows, so the negative sentiment is expected to persist.

Market effects

Biotech sector may see broader risk aversion as vaccine data disappoints.

U.S. biotech stocks could face short‑term weakness.

Limited to investors with exposure to Moderna and similar biotech pipelines.

Counterpoint

If the data later proves clinically meaningful, the sell‑off could be overdone, presenting a buying opportunity.

Key entities

  • Moderna Inc.

    Biotech firm developing a melanoma vaccine; subject of the price plunge.

Related articles

$MRNAMed

Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.

Moderna's (MRNA) cancer vaccine showed positive Phase 3 results, reducing recurrence or death risk by 42% with Merck's Keytruda, but shares fell 25% as results narrowly missed high expectations. Analysts later noted additional benefits, including a 58% risk reduction after six months and a favorable safety profile. The vaccine's potential extends beyond melanoma, with trials in other cancers ongoing. Despite FDA approval pending, Moderna's high valuation and preliminary data raise concerns.

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$MRNAMed

Why is Moderna stock sliding today?

Moderna (MRNA) shares fell 3.8% to $212.50 as investors reassess its valuation after its 2026 Analyst Day. The company projected higher cash costs and deferred 2027 revenue guidance, disappointing investors. A norovirus vaccine trial also failed to meet early success criteria. Insider stock sales and a weak market for growth equities added to the pressure, though Moderna will be added to the MSCI World Index on November 30.

$MRNAMed

Moderna Sinks 12% in a Week. Bancel Wants an FDA Filing “Before the End of the Year”

Moderna (MRNA) fell 12% in the week to Nov. 13 after projecting $4B+ annual costs through 2030, primarily for cancer drug development, including intismeran with Merck (MRK). CEO Bancel aims for FDA filing by year-end. Analysts' 2028 revenue estimates are below annual costs, and the stock trades at a high sales multiple. BioNTech (BNTX), a rival, expects revenue to fall 35.4% this year.